Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-1b
- Development stage
- Phase 2
- Lead developer
- Shanghai Institute of Biological Products
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Subcutaneous
01
Overview
Peginterferon alfa-1b is a type I interferon that has been chemically modified by the addition of polyethylene glycol (pegylation) to improve its pharmacokinetic properties, such as increasing its half-life and stability in the body. Like other pegylated interferons, it acts as an antiviral and immunomodulatory agent. Peginterferons bind to human type 1 interferon receptors (IFNAR1/2), activating the JAK/STAT signaling pathway, which leads to increased expression of genes involved in innate antiviral responses and immune regulation. This class of drugs is primarily used for the treatment of chronic hepatitis C infection, often in combination with other antivirals such as ribavirin[5][6]. Pegylation allows for less frequent dosing compared to non-pegylated forms.
- Other names
- Pegylated interferon alpha-1bPEG-IFN-alpha-1bPEG-IFN-alpha1bPEG-IFN-alpha 1bpeginterferon alpha-1b
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on peginterferon alfa-1b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-1b.